Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers

European Journal of Pharmaceutical Sciences

Volumn 10, Issue 1, 2000, Pages 11-16

  Chen, Xiaoyan ^a   Zhong, Dafang ^a   Blume, Henning ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SocraTec R and D   (Germany)

Author keywords

5 hydroxypropafenone; Conjugated metabolites; Propafenone; Stereoselective metabolism; Stereoselective pharmacokinetics

Indexed keywords

ANTIARRHYTHMIC AGENT; DRUG METABOLITE; PROPAFENONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; ANTI-ARRHYTHMIA AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; GLUCURONIDES; HUMANS; MALE; PROPAFENONE;

EID: 0034049593     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(99)00083-4     Document Type: Article

References (16)

1. Brode E., Mueller-Peltzer H., Hollmann M. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Meth. Find. Exptl. Clin. Pharmacol. 10:1988;717-727.
2. Funck-Brentano C., Kroemer H.K., Pavlou H., Woosley R.L., Roden D.M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br. J. Clin. Pharmac. 27:1989;435-444.
3. 2H-labeled propafenone in man. Eur. J. Metab. Pharmacokinet. 9:1984;41-55.
4. Koytchev R., Alken R.G., Mayer O., Boehm R., Ellrich A., Waldner-Koelblin G. Untersuchungen zur Bioaequivalenz von zwei oralen Propafenon Zubereitungen. Arzneim.-Forsch./Drug Res. 45:1995;542-545.
5. Kroemer H.K., Fischer C., Meese C.O., Eichelbaum M. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol. Pharmacol. 40:1991;135-142.
6. Kroemer H.K., Funck-Brentano C., Silberstein D.J., Wood A.J.J., Eichelbaum M., Woosley R.L., Roden D.M. Stereoselective disposition and pharmacological activity of propafenone enantiomers. Circulation. 79:1989;1068-1076.
7. Li G., Gong P.L., Qiu J., Zeng F.D., Klotz U. Stereoselective steady state disposition and action of propafenone in Chinese subjects. Br. J. Clin. Pharmacol. 46:1998;441-445.
8. Lou Y.Q., Ying L., Bertilsson L., Sjoeqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. II. 8562:1987;852-853.
9. Malfatto G., Zaza A., Forster M., Sodowick B., Danilo P., Rosen M.R. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J. Pharmacol. Exp. Ther. 246:1988;419-426.
10. Mehvar R. Apparent stereoselectivity in propafenone uptake by human and rat erythrocytes. Biopharm. Drug Dispos. 12:1991;299-310.
11. Siddoway L.A., Thompson K.A., McAllister C.B., Wang T., Wilkinson G.R., Roden D.M., Woosley R.L. Polymorphism of propafenone metabolism and disposition in man; clinical and pharmacokinetic consequences. Circulation. 75:1987;785-791.
12. 1-acid glycoprotein: assessing experimental design and data evaluation. J. Pharm. Biomed. Anal. 12:1994;1295-1302.
13. Stoschitzky K., Klein W., Stark G., Stark U., Zerning G., Graziadei I., Lindner W. Different stereoselective effects of (R)- and (S)-propafenone: Clinical, pharmacologic, eletrophysiologic, and radioligand binding studies. Clin. Pharmacol. Ther. 47:1990;740-746.
14. Volz M., Mitrovic V., Thiemer J., Schlepper M. Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites. Arzneim.-Forsch./drug Res. 45:1995;246-249.
15. Von Philipsborn G., Gries J., Hofmann H.P., Kreiskott H., Kretzschmar R., Mueller C.D., Raschack M. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzeim.-Forsch./Drug Res. 34:1984;1489-1497.
16. Zhong D.F., Chen X.Y. Enantioselective determination of propafenone and its metabolites in human plasma by liquid chromatography-mass spectrometry. J. Chromatogr. B. 721:1999;67-75.